ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1417	National Cancer Institute	Html	en	Stomach (Gastric) Cancer Prevention (PDQ®)–Health Professional Version	Risk factors for stomach (gastric) cancer include certain health conditions (e.g., atrophic gastritis, pernicious anemia, H. pylori infection), genetic factors (e.g., Li-Fraumeni syndrome), or environmental factors (e.g., diet, smoking). Review the evidence on these and other risk factors and interventions to prevent stomach cancer in this expert-reviewed summary.	randomized placebo-controlled trial 0.595383 gastric adenomatous polyps 0.679902 experimental animal models 0.575229 infected family members 0.578256 antioxidant dietary supplements 0.574787 H. pylori 0.663672 annual incidence rates 0.588818 secondary prevention measures 0.572741 age-adjusted incidence rate 0.59463 statistically significant reduction 0.578799 combined antioxidant groups 0.572868 H. pylori infection 0.650947 high H. pylori 0.585004 family members 0.581961 gastric cancer mortality 0.686327 endoscopic resection techniques 0.578064 placebo group 0.585452 chemoprevention trial 0.590009 H. pylori-infected family 0.583244 Li Fraumeni syndrome 0.58425 intestinal metaplasia 0.628781 advanced premalignant lesions 0.570945 protective effects 0.575049 low selenium content 0.586292	statistically significant effect 0.623477 Beta Carotene trial 0.587524 United States 0.702911 gastric cancer incidence. 0.664051 precancerous gastric lesions. 0.647932 5-year survival rate 0.635247 gastric cancer cases 0.674324 gastric cancers 0.625749 gastrointestinal cancers 0.575893 H. pylori-infected people 0.581367 overall 5-year survival 0.57409 beta carotene 0.671292 small randomized trial 0.598139 gastric cancer 0.97116 gastric adenocarcinoma. 0.625249 eradication therapy 0.572355 Chinese medical journal 0.572216 vitamin supplementation 0.570623 statistically significant regression 0.573687 chronic atrophic gastritis 0.586209 gastric cancer. 0.610162 close family members. 0.576811 family history 0.58364 steady incidence rates 0.587586	CLICK HERE
1597	National Cancer Institute	Html	en	Renal Cell Cancer Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of renal cell cancer.	clinical trial 0.367191 treatment 0.366101 new treatment 0.252341 cancer treatment 0.244932 renal cell cancer 0.966092 blood vessels 0.211783 cancer cells 0.348136 body 0.231872 blood 0.231431 PDQ cancer information 0.239381	kidney 0.278858 clinical trial search 0.226212 cancer clinical trials 0.248142 palliative therapy 0.250231 radiation therapy 0.306887 National Cancer Institute 0.215087 clinical trials 0.539491 information 0.242909 Recurrent renal cell 0.204258 nearby lymph nodes 0.232113	CLICK HERE
1681	National Cancer Institute	Html	en	Pheochromocytoma and Paraganglioma Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of pheochromocytoma and paraganglioma.	predictive genetic testing 0.546307 SDHD gene mutations 0.515875 Eur J Endocrinol 0.518575 Mayo Clin Proc 0.6693 Cancer Registry Data 0.51437 Engl J Med 0.526531 gastric stromal sarcoma 0.611907 hypertensive patients 0.517324 Carney JA 0.521579 relatively low specificity 0.519758 succinate dehydrogenase subunit 0.517616 family members 0.522519 secondary hypertension 0.527498 extra-adrenal paraganglioma 0.541601 patients 0.689236 pheochromocytoma 0.980646 recurrent disease 0.531233 Nat Genet 0.533038 Anderson GH Jr 0.515558 Clin Endocrinol Metab 0.833928 Young WF Jr 0.733968 blood pressure clinic 0.513794 certified genetic counselor 0.538726 apparently sporadic pheochromocytomas 0.521625 familial pheochromocytoma 0.636594	specific genetic mutation 0.541317 et al. 0.643614 Acta Med Scand 0.520675 sporadic pheochromocytoma 0.676644 hereditary syndromes 0.539521 Hum Mol Genet 0.527412 Additional functional imaging 0.525724 lower baseline risk 0.519277 nonsyndromic pheochromocytoma 0.636272 Endocrinol Metab Clin 0.581599 asymptomatic at-risk family 0.525477 hereditary syndrome 0.626484 CT imaging 0.547645 functional imaging alternatives 0.520963 Abstract 0.735482 unilateral pheochromocytoma 0.711773 Arch Intern Med 0.518188 carney triad 0.518951 high false-positive rate 0.514503 succinate dehydrogenase 0.527913 genetic testing 0.726041 apparently sporadic cases 0.53892 familial paraganglioma 0.533705 Cancer Genetics Services 0.525523	CLICK HERE
1683	National Cancer Institute	Html	en	Levels of Evidence for Cancer Genetics Studies (PDQ®)–Health Professional Version	Information about how to weigh the strength of the evidence obtained in cancer genetics research studies.	evidence 0.90522 founder pathogenic variants 0.607927 particular familial cancer 0.575132 uncertain clinical validity 0.627303 Additional molecular studies 0.560778 naturally occurring populations 0.544454 cancer genetics 0.691619 specific cancer predisposition 0.575811 genetic variant 0.654078 stringent clinical criteria 0.562657 public health decisions 0.545838 linkage studies 0.6723 PDQ editorial boards 0.553508 genetic trait 0.600811 pathogenic variant 0.819319 genetic assessment 0.654469 specific genetic variant 0.631207 study design 0.568851 similar family histories 0.661472 randomized clinical trials 0.593831 genetic tests 0.632916 clinical condition 0.678588 specific pathogenic variant 0.648511 different cut-off points 0.557549 early breast cancer 0.569442	variant classification 0.551223 new evidence 0.642949 particular genetic mode 0.574967 family history information 0.559208 dramatic cancer aggregation 0.566187 general population 0.606787 strongest evidence 0.703859 analytic validity 0.833034 specific cancer susceptibility 0.578074 positive test result 0.563425 term pathogenic variant 0.684458 pathogenic variants 0.624356 positive test 0.563624 different expert panels 0.553682 cancer genetic testing 0.643637 well-designed quasi-experimental studies 0.586898 limited evidence 0.559825 risk management decisions 0.57484 well-designed descriptive studies 0.584976 cancer genetics testing 0.58578 clinical validity 0.930443 cancer risk 0.638478 cancer 0.767744 Cancer Genetics Overview 0.616265	CLICK HERE
1693	National Cancer Institute	Html	null	Childhood Hematopoietic Cell Transplantation (PDQ®)–Health Professional Version	Blood and bone marrow transplantation involves the infusion of blood stem cells into a patient to reconstitute the blood system. Learn about transplant types, cell selection, and short- and long-term complications in this expert-reviewed summary.			CLICK HERE
1852	National Cancer Institute	Html	es	Tratamiento del sarcoma de Kaposi (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento del sarcoma de Kaposi.	Kaposi sarcoma with 0.314018 preventing kaposi 0.313966 Moritz Kaposi 0.309028 Trials Group Oncology 0.302538 Kaposi africano 0.309508 cutaneous aids-related kaposi 0.30771 kaposi's sarcoma 0.991554 progressive aids-related kaposi 0.307625 sarcoma with paclitaxel 0.306043 herpesvirus-like dna 0.302234 survival among hiv-infected 0.302423 treatment with high 0.30236 classic kaposi 0.311511 beam therapy 0.302479 Radiat Oncol Biol 0.305359 highly active 0.305764 aids-related kaposi sarcoma 0.417048 Kaposi's sarcoma-associated 0.30807 Kaposi's sarcoma from 0.313495 immunodeficiency virus-associated kaposi 0.30747 Natl Cancer Inst 0.305462 active antiretroviral therapy 0.313159 epidemic kaposi sarcoma 0.312845 AIDS-associated Kaposi sarcoma 0.331004 patients with 0.308166	radiation therapy 0.302199 Oral Kaposi sarcoma 0.311958 SK pulmonares 0.30414 Group Oncology Committee 0.302045 Kaposi's sarcoma with 0.379286 with kaposi 0.308785 HIV-associated Kaposi sarcoma 0.319062 Clinical Trials Group 0.322249 pegylated liposomal doxorubicin 0.307131 Kaposi's sarcoma receiving 0.31211 Kaposi's Sarcoma Study 0.313825 acquired immunodeficiency 0.307622 Oncology Committee 0.302366 non-visceral classic kaposi 0.307333 cutaneous kaposi 0.311944 trasplante renal 0.302536 AIDS Clinical Trials 0.324534 Clin Oncol 0.347601 resembling kaposi 0.307994 Oncol Biol Phys 0.305455 Pulmonary Kaposi sarcoma 0.312483 lesiones cutáneas 0.312534 Safai B 0.309301 acquired immune deficiency 0.302495	CLICK HERE
1853	National Cancer Institute	Html	es	Tratamiento de los tumores de hipófisis (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento de los tumores de hipófisis.	pituitary tumors 0.728644 apoplejía hipofisaria 0.422211 general adenomas gonadotropos 0.447102 gonadotroph adenomas 0.512689 Sin embargo 0.480821 pituitary carcinoma 0.526345 adenomas lactótropos 0.483762 Endocrinol Invest 0.422936 tumores gonadotropos 0.422871 tumores celulares productores 0.42814 tumores productores 0.449036 Couldwell WT 0.451028 Asa SL 0.451558 tumores endocrinos 0.42423 adenomas corticotropos 0.483433 Di Sarno A 0.42917 Kovacs KT 0.42311 Clin Endocrinol Metab 0.711638 ACTH secreting pituitary 0.441137 Neurosurg Focus 0.422719 adenomas gonadotropos 0.63232 Yeh PJ 0.462771 Chen JW 0.457982 case report 0.519998 Ezzat S 0.451653	Levy A 0.45572 adenomas tirotropos 0.47717 Long-term survival with 0.423122 pituitary adenoma 0.992345 Scheithauer BW 0.524034 invasive pituitary tumors 0.460006 adenomas somatotropos 0.480811 Subclinical adenomas 0.440961 Surg Oncol 0.463881 to functional classification 0.441148 occult adenomas 0.439818 secreting pituitary neoplasia 0.430766 Neurol Neurosurg Psychiatry 0.513976 Colao A 0.424448 Kovacs K 0.448425 with acth-secreting carcinoma 0.427044 systematic review 0.423136 Laws ER Jr 0.437305 pituitary tumors with 0.465003 medical management 0.455666 thyrotropin-secreting pituitary adenoma 0.457958 Adenomas benignos 0.45094 hipófisis productores 0.733158 Horvath E 0.435361	CLICK HERE
1989	National Cancer Institute	Html	es	Cuidados médicos de apoyo en niños (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca de la peculiaridad de los asuntos que surgen durante y después del tratamiento en los niños con cáncer, y como sobrevivientes adultos de cáncer.	etapa final 0.974283 posibles efectos tardíos 0.445113 células madre 0.448459 adultos jóvenes 0.631616 personas jóvenes 0.478657 posibles tratamientos 0.424654 siguientes aspectos 0.421705 cáncer causa estrés 0.501532 apoyo social escaso 0.437899 siguientes tipos 0.415041 largo plazo 0.418906 efectos tardíos 0.530812 familia reaccionarán 0.418853 National Cancer Institute 0.415958 siguientes riesgos 0.411551	siguientes maneras 0.446878 Instituto Nacional 0.427962 síntomasEl trastorno 0.423462 Cuidado paliativo 0.412419 distintos miembros 0.413316 tratamiento ayuda 0.457106 suicidioUn número 0.419685 siguientes efectos 0.419968 posibles efectos 0.465562 Physician Data Query 0.458553 sistema nervioso central 0.433857 mayores probabilidades 0.421125 Estados Unidos 0.416849 mejores tratamientos 0.417691	CLICK HERE
15635	National Cancer Institute	Html	en	Step 4: Award Negotiation & Issuance	Before a grant can be awarded and accepted, several pre-award activities must happen to formalize the partnership. Ensuring compliance with federal laws, a review of costs and a negotiation of the appropriate funding level must all happen in order to rece	applicant institution 0.49498 NoA 0.545113 NIH eRA Commons 0.538439 HHS requirements 0.455116 applicant’s business 0.43403 special terms 0.42079 business/administrative management perspective 0.537644 initial budget period 0.503089 grants management specialist 0.84443 subsequent budget periods 0.62245 NIH official 0.455564 multiple pre-award activities 0.51965 award 0.677162 post-award process 0.430443 Grants Administration staff 0.556889 pre-award process 0.432795 terms 0.443034 Noncompeting Award Process 0.543798 special conditions 0.423887 new recipient requirements 0.531908 research staff 0.423565 Associated F&A costs 0.474288 HHS Congressional Liaison 0.509654	grants management 0.935861 NIH Grants Policy 0.596078 specialized terms 0.42458 grants specialist 0.462503 categorical budget 0.451864 NCI staff 0.518462 award information 0.450047 management officer certifies 0.491818 awarding office 0.423573 HHS Payment Management 0.546384 NIH GPS 0.461713 overall scientific endeavor 0.511733 review recommendations 0.498295 Initial peer review 0.489678 grants management officer 0.679819 budget category 0.426444 NIH Office 0.466998 institute special monitoring 0.484399 policy requirements 0.426959 appropriate funding level 0.509975 pre-award negotiation process 0.500978 legally binding requirements 0.48831 award notices 0.446172	CLICK HERE
16649	National Cancer Institute	Html	en	Track 4: Cancer Prevention Product Research and Review for Postdoctoral Research Fellows	NCI and FDA collaborate to train individuals in the medical product development and application process. Learn more about this cancer training program.	regulatory research 0.47135 pharmacology/toxicology branch 0.439495 cancer prevention trials 0.576995 limited preclinical data 0.531474 NCI fellows 0.61137 non-clinical fellows 0.591774 FDA scientific review 0.564313 related regulatory experience 0.528845 Fellowship Program 0.512424 IRB approval process 0.551558 treatment endpoints 0.45623 application guidelines 0.486651 clinical trials 0.471521 translational research 0.452228 research goals 0.442846 early detection 0.562481 early detection trials 0.555324 various regulatory activities 0.534652 acceptable drug toxicity 0.528586 Regulatory Review Fellowships 0.520225 approval processes 0.437768 multidisciplinary cancer prevention 0.570632 particular product division 0.535827 FDA Centers 0.561203	research mentors 0.452404 product standards 0.439879 Cancer Prevention Fellowship 0.546138 regulatory pathways 0.442598 professional development activities 0.534321 earliest start date 0.490036 cancer prevention 0.942415 critical ethical issues 0.519948 product research 0.479994 clinical investigation 0.441391 appropriate clinical endpoints 0.603566 Effective Presentations Workshop 0.512774 human research subjects 0.569744 guidance document development 0.508388 public health 0.546598 Fellowship Program staff 0.506185 NCI-FDA Research 0.441603 Molecular Prevention Laboratory 0.53668 cancer prevention research 0.787983 research interests 0.453508 device development 0.439712 chemoprevention trials 0.587824 research-related regulatory overview 0.574022 Fellows Research Meetings 0.732161	CLICK HERE